BioDelivery Sciences International, Inc. (BDSI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioDelivery Sciences International, Inc. (BDSI) trades at $5.59 with AI Score 52/100 (Hold). BioDelivery Sciences International, Inc. Market cap: $577.05M, Sector: Healthcare.
Last analyzed: Feb 8, 2026BioDelivery Sciences International, Inc. (BDSI) Healthcare & Pipeline Overview
BioDelivery Sciences International, Inc. (BDSI) leverages its patented BioErodible MucoAdhesive technology to deliver innovative solutions for chronic pain and related conditions, positioning itself as a leader in specialty pharmaceuticals with a robust product pipeline and strong profit margins.
Investment Thesis
Investing in BioDelivery Sciences International, Inc. (BDSI) presents a notable opportunity due to its strong financial metrics and innovative product offerings. With a market cap of $0.58 billion and a P/E ratio of 6.80, BDSI is undervalued compared to industry peers. The company boasts a profit margin of 50.9% and a gross margin of 86%, indicating efficient operations and strong pricing power. Key growth catalysts include the increasing prevalence of chronic pain conditions and the ongoing opioid crisis, which drive demand for BDSI's products. Furthermore, the potential for international expansion and the introduction of new formulations could significantly enhance revenue streams. With a strong pipeline and a focus on specialty pharmaceuticals, BDSI is well-positioned to capture market share and deliver shareholder value in the coming years.
Based on FMP financials and quantitative analysis
Key Highlights
- Market cap of $0.58 billion reflects significant growth potential in the specialty pharmaceutical sector.
- P/E ratio of 6.80 indicates BDSI is undervalued compared to industry peers, presenting a buying opportunity.
- Profit margin of 50.9% showcases operational efficiency and strong profitability.
- Gross margin of 86% exceeds industry averages, highlighting effective cost management and pricing strategies.
- No dividend yield, indicating a focus on reinvesting earnings for growth and expansion.
Competitors & Peers
Strengths
- Innovative drug delivery technology with patent protection.
- Strong profit margins and operational efficiency.
- Established presence in the specialty pharmaceutical market.
- Diverse product portfolio addressing chronic pain and related conditions.
Weaknesses
- Limited product diversification outside of core offerings.
- Dependence on a few key products for revenue generation.
- Potential challenges in scaling operations for international markets.
- No dividend yield may deter income-focused investors.
Catalysts
- Upcoming: Potential launch of new formulations to expand product offerings.
- Ongoing: Strong sales growth of BELBUCA and Symproic driving revenue.
- Upcoming: International market entry strategies to enhance global presence.
- Ongoing: Increasing awareness of chronic pain management solutions bolstering demand.
- Ongoing: Collaborations with healthcare providers improving market access.
Risks
- Potential: Regulatory hurdles impacting product approvals and market access.
- Ongoing: Competition from generic alternatives affecting market share.
- Ongoing: Dependence on a limited number of key products for revenue.
- Potential: Economic downturns impacting healthcare spending.
Growth Opportunities
- Growth opportunity 1: The chronic pain management market is projected to reach $80 billion by 2026, driven by an aging population and increasing prevalence of chronic conditions. BDSI's BELBUCA and Symproic products are uniquely positioned to capture this market, leveraging their innovative delivery mechanisms to provide effective pain relief and reduce opioid dependency.
- Growth opportunity 2: The global migraine treatment market is expected to grow to $5 billion by 2025. BDSI's ELYXYB, as a targeted solution for migraine relief, can tap into this expanding market, particularly as awareness of effective treatments increases among healthcare providers and patients.
- Growth opportunity 3: The opioid crisis has led to a significant shift in pain management practices, with a growing emphasis on non-opioid alternatives. BDSI's focus on developing products like Symproic positions the company to benefit from this trend, as healthcare providers seek safer options for managing pain.
- Growth opportunity 4: International expansion represents a significant growth avenue for BDSI. By entering markets in Europe and Asia, where chronic pain and opioid-related issues are prevalent, the company can diversify its revenue streams and enhance its global footprint.
- Growth opportunity 5: The development of new formulations and delivery methods could unlock additional revenue streams for BDSI. By investing in research and development, the company can enhance its product portfolio and address more diverse patient needs, further solidifying its market position.
Opportunities
- Expansion into international markets for revenue growth.
- Increasing demand for non-opioid pain management solutions.
- Development of new formulations to enhance product offerings.
- Growing awareness and acceptance of specialty pharmaceuticals.
Threats
- Intense competition from both specialty and generic pharmaceutical companies.
- Regulatory challenges in drug approval and market entry.
- Market volatility affecting healthcare spending and reimbursement.
- Potential backlash against opioid-based treatments impacting sales.
Competitive Advantages
- Patented drug delivery technology provides a competitive edge.
- Strong product portfolio addressing significant market needs.
- High profit margins indicate operational efficiency.
- Established relationships with healthcare providers enhance market access.
- Focus on specialty pharmaceuticals reduces competition from generic alternatives.
About BDSI
Founded in 1997 and headquartered in Raleigh, North Carolina, BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products aimed at treating chronic conditions. The company's unique approach is centered around its patented BioErodible MucoAdhesive (BEMA) technology, which utilizes a small erodible polymer film designed for application to the buccal mucosa. This technology allows for more effective drug delivery, enhancing the therapeutic effects of its products. BDSI's flagship products include BELBUCA, a buprenorphine buccal film specifically formulated for chronic pain management, and Symproic, which addresses opioid-induced constipation in adults suffering from chronic non-cancer pain. Additionally, BDSI offers ELYXYB, a celecoxib oral solution for migraine treatment, and ONSOLIS, a fentanyl buccal soluble film for managing breakthrough pain in cancer patients. The company operates primarily within the United States but also has aspirations for international expansion. As of March 2022, BDSI operates as a subsidiary of Collegium Pharmaceutical, Inc., which further strengthens its market position and resource capabilities. BDSI's commitment to innovation and patient-centric solutions has positioned it as a key player in the specialty pharmaceutical landscape, with a focus on addressing unmet medical needs through advanced drug delivery technologies.
What They Do
- Develops and commercializes pharmaceutical products for chronic conditions.
- Utilizes patented BioErodible MucoAdhesive technology for drug delivery.
- Offers BELBUCA for chronic pain management.
- Provides Symproic for opioid-induced constipation treatment.
- Markets ELYXYB for migraine relief.
- Sells ONSOLIS for breakthrough cancer pain management.
Business Model
- Generates revenue through the sale of specialty pharmaceutical products.
- Focuses on innovative drug delivery technologies to enhance patient outcomes.
- Operates primarily in the U.S. market with plans for international expansion.
- Targets chronic conditions with high unmet medical needs.
- Collaborates with healthcare providers to improve treatment options.
Industry Context
The specialty pharmaceutical industry is experiencing robust growth, driven by an increasing demand for innovative therapies to manage chronic conditions. The global market for specialty drugs is projected to reach $500 billion by 2025, with a CAGR of over 10%. BDSI operates in a competitive landscape alongside peers such as ACCD, ALIM, APEN, EXAI, and GRALV, each vying for market share in the lucrative pain management and opioid alternatives sectors. With its unique drug delivery technologies, BDSI is well-positioned to capitalize on these trends and address the growing needs of patients and healthcare providers.
Key Customers
- Healthcare providers including hospitals and clinics.
- Patients suffering from chronic pain and related conditions.
- Pharmaceutical distributors and wholesalers.
- Insurance companies covering specialty medications.
- Research institutions focusing on chronic disease management.
Financials
Chart & Info
BioDelivery Sciences International, Inc. (BDSI) stock price: $5.59 (+0.00, +0.00%)
Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Mar 16, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BDSI.
Price Targets
Wall Street price target analysis for BDSI.
MoonshotScore
What does this score mean?
The MoonshotScore rates BDSI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
BDSI Healthcare Stock FAQ
What does BioDelivery Sciences International, Inc. do?
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company that develops and commercializes innovative drug delivery solutions for chronic conditions. Utilizing its patented BioErodible MucoAdhesive technology, BDSI offers products like BELBUCA for chronic pain and Symproic for opioid-induced constipation, aiming to address significant unmet medical needs in the healthcare market.
Is BDSI stock worth researching?
BDSI stock presents a notable research candidate due to its strong financial metrics, including a profit margin of 50.9% and a gross margin of 86%. With a P/E ratio of 6.80, the stock appears undervalued compared to peers, and the company's focus on innovative pain management solutions positions it well for future growth, particularly as demand for non-opioid treatments increases.
What are the main risks for BDSI?
BDSI faces several risks, including regulatory hurdles that could impact product approvals and market access. Additionally, the company competes in a crowded market with both specialty and generic pharmaceutical companies, which may affect its market share. Economic downturns could also impact healthcare spending, posing a risk to revenue generation.
What are the key factors to evaluate for BDSI?
BioDelivery Sciences International, Inc. (BDSI) currently holds an AI score of 52/100, indicating moderate score. The stock trades at a P/E of 6.8x, below the S&P 500 average (~20-25x), potentially signaling value. Key strength: Innovative drug delivery technology with patent protection.. Primary risk to monitor: Potential: Regulatory hurdles impacting product approvals and market access.. This is not financial advice.
How frequently does BDSI data refresh on this page?
BDSI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BDSI's recent stock price performance?
Recent price movement in BioDelivery Sciences International, Inc. (BDSI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative drug delivery technology with patent protection.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BDSI overvalued or undervalued right now?
Determining whether BioDelivery Sciences International, Inc. (BDSI) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 6.8. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BDSI?
Before investing in BioDelivery Sciences International, Inc. (BDSI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of February 2026.